EUVIMEDEUVIMED entdecken
Crossref

A Study to Assess the Efficacy of the Sofosbuvir/Daclatasvir Combination as a Pan-genotypic Treatment for Hepatitis C without HCV Genotype Determination

Abere Sarah, Boma Oyan, Mbang, Koofreh-Ada, Alali, Dan-Jumbo, Hannah, Omunakwe

Nigerian Medical Journal · 07.02.2024

DOI: 10.60787/nmj-64-1-240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nigerian Medical Journal, erschienen am 07.02.2024. Verfasst von Abere Sarah und 7 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Viral hepatitis C (HCV) is a global health challenge affecting at least 3.3% of the world’s population. Saharan Africa still battles with the under-diagnosis and poor access to diagnostic facilities occasioned by a lack of manpower/facilities to treat infected persons bringing about an increase in HCV-associated morbidity and mortality. The goal of this prospective observational study is to assess the efficacy of the sofosbuvir/daclatasvir combination as a pan-genotypic treatment for hepatitis C without HCV genotype determination in patients with hepatitis C attending the hepatology clinic at Rivers State University Teaching Hospital (RSUTH). Methodology: 150 HCV RNA-positive patients were enlisted into the study. Their socio-demographic factors and clinical and laboratory parameters including HCV RNA pre- and post-treatment were assessed. Treatment-eligible patients received sofosbuvir 400mg and Daclatasvir 60/90mg for 12 weeks which was extended to 24 weeks in patients with decompensated liver disease. Treatment success was defined as undetectable HCV RNA 12 weeks after completion of therapy (SVR-12).

Results

109 of the 150 recruited patients were eligible for treatment. The male to female ratio of the study population was 79(52.7%):71(49.3%) with a mean age of 47.78±13.39 (18-74) years. 86(78.9%) of the 109 treated patients had undetectable HCV RNA at SVR-12 and this was most likely to occur in patients with low viremia (OR=2.52, 95%CI=0.985-6.436, p=0.050). Extension of treatment duration played no apparent role in the achievement of SVR-12 (SVR-12=33.3%) however, previously treated HCV patients had a better outcome.

Conclusion

Sofosbuvir/daclatasvir pan-genotypic therapy is modestly effective for the treatment of HCV patients without genotyping.

Schlagwörter

hepatitis Csofosbuvirdaclatasvirsustained virological responseHCV RNA viral loadtreatment durationdecompensated liver diseasetreatment efficacy

Zitieren

APA

Sarah, A., Oyan, B., Mbang, Koofreh-Ada, Alali, Dan-Jumbo, Hannah, & Omunakwe (2024). A Study to Assess the Efficacy of the Sofosbuvir/Daclatasvir Combination as a Pan-genotypic Treatment for Hepatitis C without HCV Genotype Determination. Nigerian Medical Journal. https://doi.org/10.60787/nmj-64-1-240

Vancouver

Sarah A, Oyan B, Mbang, Koofreh-Ada, Alali, Dan-Jumbo, et al. A Study to Assess the Efficacy of the Sofosbuvir/Daclatasvir Combination as a Pan-genotypic Treatment for Hepatitis C without HCV Genotype Determination. Nigerian Medical Journal. 2024. doi:10.60787/nmj-64-1-240

BibTeX
@article{Sarah2024,
  author = {Sarah, Abere and Oyan, Boma and Mbang and Koofreh-Ada and Alali and Dan-Jumbo and Hannah and Omunakwe},
  title = {A Study to Assess the Efficacy of the Sofosbuvir/Daclatasvir Combination as a Pan-genotypic Treatment for Hepatitis C without HCV Genotype Determination},
  journal = {Nigerian Medical Journal},
  year = {2024},
  doi = {10.60787/nmj-64-1-240}
}
Kostenlos starten →